116 related articles for article (PubMed ID: 583231)
21. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
Schwartzkopff W; Zschiedrich M
Med Klin; 1978 Feb; 73(7):231-9. PubMed ID: 203832
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
Arntz HR; Klemens UH; Vollmar LJ; Lang PD
Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
[TBL] [Abstract][Full Text] [Related]
23. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
[TBL] [Abstract][Full Text] [Related]
24. Effect of calcium p-chlorphenoxyisobutyrate and calcium carbonate on plasma lipids and lipoproteins of patients with hyperlipoproteinaemia.
Koskinen P; Inkovaara J; Ala-Kaila K; Salo M; Nikkari T
Ann Clin Res; 1977 Dec; 9(6):335-41. PubMed ID: 356720
[TBL] [Abstract][Full Text] [Related]
25. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
[TBL] [Abstract][Full Text] [Related]
26. Plafibride treatment and serum lipids in hyperlipoproteinemias.
Rodriguez F; López IM; Jover E
J Med; 1987; 18(3-4):153-63. PubMed ID: 3323393
[TBL] [Abstract][Full Text] [Related]
27. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
Micheli H; Pometta D; Gustafson A
Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].
Paltauf F; Pristautz H; el Eisch IA
Acta Med Austriaca; 1977; 4(3):120-4. PubMed ID: 930544
[TBL] [Abstract][Full Text] [Related]
29. [Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Reuter W
Z Gesamte Inn Med; 1982 Oct; 37(20):682-8. PubMed ID: 6818779
[TBL] [Abstract][Full Text] [Related]
30. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Lopez Rodriguez J; Martorell J
Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
[TBL] [Abstract][Full Text] [Related]
31. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Nye ER; Sutherland WH; Temple Wa
N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
[TBL] [Abstract][Full Text] [Related]
32. [The effect of fenofibrate in various types of hyperlipoproteinemias].
Sucić M
Lijec Vjesn; 1989 Mar; 111(3):93-7. PubMed ID: 2747411
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of primary hyperlipoproteinemias of type IIB and IV with butylbiguanide and clofibrate (author's transl)].
Koschinsky T; Gries FA; Schwandt P; Weisweiler P; Hansen W; Nijssen J; Beckmann R
MMW Munch Med Wochenschr; 1977 May; 119(20):701-4. PubMed ID: 195201
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)].
Koschinsky T; Lenhard P; Gries FA; Vogelberg KH; Wolfram G; Lang PD; Vollmar J
Med Klin; 1977 Sep; 72(38):1537-43. PubMed ID: 904549
[TBL] [Abstract][Full Text] [Related]
35. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
[TBL] [Abstract][Full Text] [Related]
36. [Comparative studies of the lipid-lowering activity of etiroxate hydrochloride and dextrothyroxine (author's transl)].
Schwartzkopff W; Russ E
MMW Munch Med Wochenschr; 1975 May; 117(19):827-30. PubMed ID: 805950
[TBL] [Abstract][Full Text] [Related]
37. [Clofibrate therapy--the status quo].
Reuter W
Z Gesamte Inn Med; 1982 Jan; 37(2):59-63. PubMed ID: 7080553
[TBL] [Abstract][Full Text] [Related]
38. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
[TBL] [Abstract][Full Text] [Related]
39. [Effect of 1 month's treatment with Bezalip on the serum lipids and lipoproteins of patients with different types of hyperlipoproteinemias].
Kiriakov A; Malamov E; Apostolova Iu; Tsenov I; Tinterova Z
Vutr Boles; 1983; 22(3):74-81. PubMed ID: 6649587
[TBL] [Abstract][Full Text] [Related]
40. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Mertz DP; Loewer H; Suermann I
Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
